Our findings are consistent with the hypothesis that in some patients with PML, pembrolizumab reduces JC viral load and increases CD4+ and CD8+ activity against the JC virus; clinical improvement or stabilization occurred in five of the eight patients who received pembrolizumab. T h e ne w e ngl a nd jou r na l o f m e dicine P rogressive multifocal leukoencephalopathy (PML) is an aggressive, opportunistic brain infection caused by the JC virus, a ubiquitous polyomavirus that is estimated to latently infect the kidneys in more than 50% of healthy adults. In the context of cellular immunodeficiency, JC virus can undergo genetic rearrangements in noncoding regions and can transform to a neurotropic virus that is able to infect glial cells and cause PML. 1 The incidence of death associated with PML varies depending on the nature of the underlying cause and on the degree of immunosuppression. Success in treating PML has been limited, [2] [3] [4] [5] [6] and most efforts have been aimed at restoration of immunity. 1 Programmed cell death protein 1 (PD-1) is present on the surface of T cells and acts as a negative regulator of immune responses. The protein is up-regulated on activated immune cells and is expressed persistently on chronically activated immune cells, where its engagement leads to progressive loss of T-cell functions, including T-cell proliferation, and to cytokine and granzyme B production; loss of these effector functions results in a reduction in antigen-specific immune responses. Blocking PD-1 reinvigorates antitumor immune activity directed at a variety of cancers. 7 In the context of chronic infection, PD-1 expression may lead to impaired viral clearance. For example, blocking the PD-1 pathway in an animal model of lymphocytic choriomeningitis infection was shown to restore T-cell effector functions, which led to a reduction in viral load. 8 PD-1 expression is up-regulated on CD4+ and CD8+ cells in patients with PML and is specifically enriched on JC virus-specific CD8+ cells. 9 We have observed increased expression of PD-1 and programmed death ligand 1 (PD-L1) in PML lesions from autopsy specimens (unpublished data). We found that patients with PML showed a higher percentage of PD-1 expression on CD4+ and CD8+ lymphocytes in blood and in cerebrospinal fluid (CSF) than healthy controls (Figs. S1 through S3 in the Supplementary Appendix, available with the full text of this article at NEJM.org). We hypothesized that expression of the PD-1-PD-L1 pathway may limit successful containment or clearance of JC virus and that treatment of PML with PD-1 blockade could reinvigorate specific antiviral immune activity.
Me thods
We describe here eight adults with PML who were enrolled at the National Institutes of Health (NIH) for the Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) (ClinicalTrials .gov number, NCT01730131) and for the Inflammatory and Infectious Diseases of the Nervous System study (NCT02435810), both of which were approved by the institutional review board at the NIH. All the data presented here were collected during the course of clinical care and not as part of a protocol-driven clinical trial of pembrolizumab, and the drug was not administered with the purpose of treating the disorder underlying PML. The drug was given on a compassionate-use basis. All the participants in the two studies provided written informed consent for participation and separately provided specific consent to receive off-label treatment with pembrolizumab. There was no industry involvement in this study.
Patients received pembrolizumab at a dose of 2 mg per kilogram of body weight, administered intravenously, every 4 to 6 weeks, for a maximum of three doses. Clinical evaluations were performed at each treatment and follow-up visit and included neurologic examinations and determination of disability with the use of the modified Rankin scale (a 7-point disability rating scale with scores ranging from 0 [no deficit] to 6 [death]). Laboratory testing included a complete blood count and a metabolic panel, and magnetic resonance imaging (MRI) was performed as described in the Supplementary Appendix. MRIs were interpreted by the study neuroradiologist, and assessments of lesion burden observed on imaging were qualitative.
We performed immunophenotyping in blood and CSF using multicolor flow cytometry, as described in the Supplementary Appendix. 10 JC virus genomic DNA was detected in CSF samples with the use of an ultrasensitive multiplex quantitative polymerase-chain-reaction (PCR) assay that was certified by the Clinical Laboratory Improvement Amendments program. This assay distinguishes the less pathogenic archetype variant typically excreted in the urine from the PML-associated prototype variant found in the blood, CSF, and brain of patients with PML. 11, 12 The assay has a detection Pembrolizumab for Multifocal Leukoencephalopathy limit of 10 copies per milliliter and targets the highly conserved T antigen coding region for identification and quantitation and the noncoding control region to differentiate archetype variants from prototype variants.
To estimate the magnitude of antiviral responses, we expanded virus-reactive cells ex vivo using commercially available overlapping peptide libraries derived from the surface viral antigens VP1 and LT, which are known to be the most relevant surface viral antigens immunologically, and subsequently measured the number of cytokine-producing T cells. Details are provided in the Supplementary Appendix.
R esult s

Patients
The characteristics of the patients at baseline are summarized in Table 1 . Seven patients presented with neurologic signs and symptoms that had progressed in the months preceding their first evaluation at the NIH; the condition of the eighth patient (Patient 1) had stabilized clinically, but the patient had persistent JC virus in the CSF. Among the eight patients, the JC viral load in the CSF at the initial NIH evaluation ranged from 63 to 28,350 copies per milliliter. The immune conditions underlying PML were human immunodeficiency virus (HIV) infection in two patients, chronic lymphocytic leukemia (CLL) in two patients, remote history of Hodgkin's lymphoma in one patient, non-Hodgkin's lymphoma in one patient, and idiopathic lymphopenia in two patients. Lymphopenia across all categories of immune diseases variably affected the CD4+, CD8+, and CD19+ cell count; baseline values ranged from 13 to 580 per cubic millimeter for CD4+, from 47 to 1588 per cubic millimeter for CD8+, and from 10 to 553 per cubic millimeter for CD19+.
The degree of clinical disability as a result of PML varied: two patients had mild disability, with preserved ability to look after their own affairs (score of 2 on the modified Rankin scale); two had moderate disability but had preserved ability to walk without assistance (score of 3 on the modified Rankin scale); and four were severely disabled, including inability to walk or to attend to bodily needs without assistance (score of 4 on the modified Rankin scale). The most common deficits observed at the initial NIH evaluation were ataxia (in five patients), cortical visual impairment or hemianopia (in four patients), and cognitive dysfunction (in three patients), typically associated with apathy.
Clinical Course with Pembrolizumab Treatment
The clinical course of each patient is summarized in Table 1 Patient 2 had transient worsening of neurologic symptoms during the first week after the initial infusion, with fluent aphasia associated with enlargement of a lesion in the left temporal T h e ne w e ngl a nd jou r na l o f m e dicine 286 and 98 § * CLL denotes chronic lymphocytic leukemia, CSF cerebrospinal fluid, HIV human immunodeficiency virus, IRIS immune reconstitution inflammatory syndrome, MRI magnetic resonance imaging, and PML progressive multifocal leukoencephalopathy. † Time 0 refers to the first dose of pembrolizumab. Months preceded by a minus sign refers to the number of months before treatment with pembrolizumab. ‡ The modified Rankin scale is a seven-point disability rating scale; scores range from 0 (no deficit) to 6 (death). § The value of 98 copies per milliliter is the last known value, which was measured 1 year after the last dose of pembrolizumab.
T h e ne w e ngl a nd jou r na l o f m e dicine lobe that had previously been seen on the baseline MRI scans. This lesion was not enhanced by contrast material, which suggested that the worsening of clinical symptoms was related to PML rather than to immune reconstitution inflammatory syndrome (IRIS) (Fig. S5 in the Supplementary Appendix). One patient (Patient 1 with CLL), whose condition had stabilized before receipt of pembrolizumab, had no incremental benefit from treatment, as assessed by clinical, radiologic, and virologic measures (Fig. S4 in the Supplementary Appendix). Two patients (Patient 4 with nonHodgkin's lymphoma and Patient 6 with idiopathic lymphopenia) had progressive worsening of neurologic symptoms and signs after treatment with pembrolizumab. In both patients, MRI showed increased PML lesion burden, and the PCR assay showed persistent elevation of JC viral load in the CSF. Both patients died from PML within 6 months after their initial assessment at the NIH (Figs. S7 and S9).
One patient (Patient 8 with HIV infection) had laboratory evidence of in vitro reinvigoration of anti-JC virus T-cell response within 1 month after his first infusion of pembrolizumab; reactivity against JC viral peptide LT was more than 2 times as high as the baseline level, and reactivity against JC viral peptide VP1 was more than 10 times as high as the baseline level (Fig. 1F) . His clinical course was characterized by subjective fluctuation of symptoms without objective change on neurologic examination and without a clear temporal association between the degree of symptoms and treatment. MRI showed stabilization of the lesions after the first two infusions of pembrolizumab; during the next 6 months, the JC viral load in the CSF declined to 53 copies per milliliter and clinical symptoms stabilized. His condition remained stable until 11 months after the first infusion, at which time he had clinical and imaging recurrence of PML and the JC viral load in the CSF had increased to 404 copies per milliliter. He received an additional dose of pembrolizumab, which was associated with clinical and radiologic stabilization and a decline in the JC viral load to 273 copies per milliliter by month 13 (Table 1 and Fig. 1, and Fig. S11 in the Supplementary Appendix). At 24 months after the first infusion, the clinical features of PML in this patient were stable, and the JC viral load in the CSF was 98 copies per milliliter.
Two adverse events occurred. Patient 5 had recurrence of a long-standing psoriatic rash in the month after treatment with pembrolizumab. Patient 6 had recurrence of a maculopapular rash, which had previously been attributed to nonspecific dermatitis affecting the chest (Table S1 in the Supplementary Appendix). With the possible exception of the event in Patient 2 described above, there were no instances of IRIS.
Laboratory Results
Pembrolizumab treatment was associated with a decrease in detection of PD-1 on lymphocytes in peripheral blood and CSF (Fig. 1A through 1D ).
Complete suppression of PD-1 expression was not achieved in the CSF lymphocytes of any patient, despite a 33 to 87% decrease in PD-1 detection on CD4+ cells and a 38 to 90% decrease in PD-1 detection on CD8+ cells after the first dose. CSF cells recovered PD-1 expression earlier than blood cells (4 to 6 weeks vs. 4 to 6 months). No substantial change in absolute CD3+, CD4+, or CD8+ cell counts was observed after treatment (data not shown).
A substantial and sustained decline in the JC viral load was observed in five patients (Patients 2, 3, 5, 7, and 8), most commonly within 1 month after the first infusion (Table 1, and Figs. S5, S6 , S8, S10, and S11 in the Supplementary Appendix). The viral load in one patient (Patient 8) reached its nadir after 6 months (Fig. S11) , despite an increase in anti-JC virus T-cell reactivity within the first month after treatment (Fig. 1F) . In the five patients who had a decline in JC viral load, the reduction in the viral load was associated with clinical and radiologic improvement or stabilization, but this temporal association was descriptive and not invariable and was not judged by a prespecified metric (Table 1, and Figs. S5, S6 , S8, S10, and S11). The degree of PD-1 expression before treatment did not correlate with clinical or virologic response to treatment (Fig. S12) .
The patients who had a reduction in the JC viral load had increased in vitro anti-JC virus activity after PD-1 blockade that was temporally associated with pembrolizumab administration (Fig. 1F, and tion in viral load, in vitro anti-JC virus T-cell activity was not enhanced, despite similar PD-1 suppression in the blood and CSF (Fig. 1E , and Fig. S15 ).
Discussion
Our investigation of pembrolizumab in the treatment of PML was initiated as a result of findings showing that PD-1 was expressed on T cells within PML lesions and also on lymphocytes in the CSF and blood of patients with PML and that PD-L1 was expressed on macrophages within PML lesions. These observations suggested that the PD-1-PD-L1 pathway might play a role in the pathogenesis of PML. Eight patients received a dose of pembrolizumab every 4 to 6 weeks, for a maximum of three doses, and serial neurologic examinations, MRI, and CSF sampling were performed for 1 to 13 months after the first infusion. In the months before the first infusion, seven of the eight patients had presented with progressive neurologic deterioration, and MRI showed enlargement of PML lesions. After treatment with pembrolizumab, five of the eight patients had clinical improvement or stabilization, and MRI showed corresponding stabilization or reduction in lesion burden; none of the patients had complete disappearance of PML lesions. The five patients whose condition stabilized or improved clinically had a reduction in JC viral load in the CSF that was temporally associated with reinvigoration of in vitro anti-JC virus cellular immune responses. Four of these five patients showed a persistent reduction in JC viral load and clinical stabilization with no recurrence of PML 16 to 26 months after receiving the last infusion. The remaining three patients had no clinical benefit from pembrolizumab. One of these patients had already had clinical, radiologic, and virologic stabilization before treatment, and his condition remained stable with no incremental improvement. The condition of the other two of these three patients continued to decline, and the patients subsequently died from PML. Treatment did not induce IRIS, as determined by serial MRI, except possibly in one patient. One patient had recurrence of psoriatic rash, and one patient had recurrence of a nonspecific dermatitic rash.
Treatment with pembrolizumab had no evident effect on the hematologic or immune disorders underlying PML, and amelioration of the primary disorder was not likely to have explained the decrease in JC viral load. However, this possibility cannot be excluded in the case of patients who had neoplastic and lymphopenic disorders. The absence of IRIS in our series may have been the result of the presence of lymphopenia, which persisted after treatment with pembrolizumab. The limitations of any conclusions that could be derived from this case series include the varied underlying diseases and degree of immune suppression, the lack of paired blood and CSF samples before and after treatment in some patients, and the small size of this study. Larger systematically conducted studies and clinical trials are warranted to ascertain the effect of pembrolizumab treatment on PML.
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